149 related items for PubMed ID: 2974290
1. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[Abstract] [Full Text] [Related]
2. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW, Uitterlinden P, de Jong FH.
Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
[Abstract] [Full Text] [Related]
3. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O, Kontturi M.
Scand J Urol Nephrol Suppl; 1988 Nov 01; 110():109-12. PubMed ID: 2973121
[Abstract] [Full Text] [Related]
4. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM, Williams G, O'Shea JP, Smith C, Yeo T, Kerle D, Bloom SR.
Urol Res; 1984 Nov 01; 12(5):249-51. PubMed ID: 6240150
[Abstract] [Full Text] [Related]
5. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
J Clin Oncol; 1987 Jun 01; 5(6):912-7. PubMed ID: 2953870
[Abstract] [Full Text] [Related]
6. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ.
Br Med J (Clin Res Ed); 1985 Jan 19; 290(6463):185-7. PubMed ID: 3155636
[Abstract] [Full Text] [Related]
7. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H, Senge T.
J Urol; 1990 Oct 19; 144(4):934-41. PubMed ID: 2144596
[Abstract] [Full Text] [Related]
8. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
Van Cangh PJ, Opsomer RJ.
J Urol; 1987 Jan 19; 137(1):61-4. PubMed ID: 2948026
[Abstract] [Full Text] [Related]
9. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Mahler C, Denis L.
Am J Clin Oncol; 1988 Jan 19; 11 Suppl 2():S127-8. PubMed ID: 2977268
[Abstract] [Full Text] [Related]
10. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
[Abstract] [Full Text] [Related]
11. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C, Verhelst J, Chaban M, Denis L.
Cancer; 1991 Feb 01; 67(3):557-9. PubMed ID: 1824680
[Abstract] [Full Text] [Related]
12. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y.
Am J Clin Oncol; 1988 Feb 01; 11 Suppl 2():S108-11. PubMed ID: 2977262
[Abstract] [Full Text] [Related]
13. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K.
J Endocrinol; 1984 Nov 01; 103(2):R1-4. PubMed ID: 6238116
[Abstract] [Full Text] [Related]
14. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS.
Cancer; 1993 Sep 01; 72(5):1685-91. PubMed ID: 7688656
[Abstract] [Full Text] [Related]
15. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Di Silverio F, Sciarra F, D'Eramo G.
Eur Urol; 1990 Sep 01; 18(1):10-5. PubMed ID: 2144819
[Abstract] [Full Text] [Related]
16. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P.
J Urol; 1988 Oct 01; 140(4):775-7. PubMed ID: 2971119
[Abstract] [Full Text] [Related]
17. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB, Ahmed SR, Shalet SM, Costello CB, Howell A, Blacklock NJ.
Br J Urol; 1986 Oct 01; 58(5):539-44. PubMed ID: 2946356
[Abstract] [Full Text] [Related]
18. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F, Serio M, D'Eramo G, Sciarra F.
Eur Urol; 1990 Oct 01; 18 Suppl 3():54-61. PubMed ID: 2151278
[Abstract] [Full Text] [Related]
19. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
Eur J Surg Oncol; 1985 Jun 01; 11(2):159-65. PubMed ID: 3159598
[Abstract] [Full Text] [Related]
20. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA, Fernandez del Moral P, Plasman JW, Pull HC, van der Meijden AP, Debruyne FM, Hutchinson FG, Furr BJ.
Eur Urol; 1990 Jun 01; 18 Suppl 3():22-5. PubMed ID: 2151271
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
